Last updated: 2026-10-09 17:39:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Processa Pharmaceuticals, Inc. (PCSA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.40, with a market capitalization of $3.97M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.11 to $11.08. This page covers its latest market performance, valuation, price trends and company information.
$3.97M | |
$1.32 | |
$938,350.00 | |
$1.11 | |
$1.35 | |
2.80M | |
226.45K | |
-- | |
$11.08 | |
$1.11 | |
-- | |
-- |
Processa Pharmaceuticals, Inc. (PCSA) is currently trading at $1.40 as of 2026-10-09 17:37:00, up 3.70% ($0.05) from the previous close of $1.35
During today's regular trading session, PCSA has traded between $1.11 and $938,350.00, with a trading volume of 2.80M shares. The current price is near the lower end of today's range.
Over the past seven days, Processa Pharmaceuticals, Inc. (PCSA) moved from $1.64 to $1.40, representing a decline of 14.63% ($0.24).
The stock traded between $1.11 and $1.85 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 25.64 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 2.9%
PCSA is currently trading at $1.40, placing it 2.9% of the way from its 52-week low of $1.11 to its 52-week high of $11.08. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 12 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Processa Pharmaceuticals, Inc. (PCSA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.